GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (NAS:ARNA) » Definitions » Asset Turnover

Arena Pharmaceuticals (Arena Pharmaceuticals) Asset Turnover : 0.00 (As of Dec. 2021)


View and export this data going back to 2000. Start your Free Trial

What is Arena Pharmaceuticals Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Arena Pharmaceuticals's Revenue for the three months ended in Dec. 2021 was $0.05 Mil. Arena Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2021 was $842.87 Mil. Therefore, Arena Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2021 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Arena Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2021 was -84.46%. It is also linked to ROA % through Du Pont Formula. Arena Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2021 was -73.85%.


Arena Pharmaceuticals Asset Turnover Historical Data

The historical data trend for Arena Pharmaceuticals's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arena Pharmaceuticals Asset Turnover Chart

Arena Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.04 0.87 - -

Arena Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Arena Pharmaceuticals's Asset Turnover

For the Biotechnology subindustry, Arena Pharmaceuticals's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arena Pharmaceuticals's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arena Pharmaceuticals's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Arena Pharmaceuticals's Asset Turnover falls into.



Arena Pharmaceuticals Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Arena Pharmaceuticals's Asset Turnover for the fiscal year that ended in Dec. 2021 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2021 )/( (Total Assets (A: Dec. 2020 )+Total Assets (A: Dec. 2021 ))/ count )
=0.054/( (1190.72+784.705)/ 2 )
=0.054/987.7125
=0.00

Arena Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2021 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2021 )/( (Total Assets (Q: Sep. 2021 )+Total Assets (Q: Dec. 2021 ))/ count )
=0.054/( (901.027+784.705)/ 2 )
=0.054/842.866
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Arena Pharmaceuticals  (NAS:ARNA) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Arena Pharmaceuticals's annulized ROE % for the quarter that ended in Dec. 2021 is

ROE %**(Q: Dec. 2021 )
=Net Income/Total Stockholders Equity
=-622.436/736.979
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-622.436 / 0.216)*(0.216 / 842.866)*(842.866/ 736.979)
=Net Margin %*Asset Turnover*Equity Multiplier
=-288164.81 %*0.0003*1.1437
=ROA %*Equity Multiplier
=-73.85 %*1.1437
=-84.46 %

Note: The Net Income data used here is four times the quarterly (Dec. 2021) net income data. The Revenue data used here is four times the quarterly (Dec. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Arena Pharmaceuticals's annulized ROA % for the quarter that ended in Dec. 2021 is

ROA %(Q: Dec. 2021 )
=Net Income/Total Assets
=-622.436/842.866
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-622.436 / 0.216)*(0.216 / 842.866)
=Net Margin %*Asset Turnover
=-288164.81 %*0.0003
=-73.85 %

Note: The Net Income data used here is four times the quarterly (Dec. 2021) net income data. The Revenue data used here is four times the quarterly (Dec. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Arena Pharmaceuticals Asset Turnover Related Terms

Thank you for viewing the detailed overview of Arena Pharmaceuticals's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Arena Pharmaceuticals (Arena Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
136 Heber Avenue, Suite 204, Park City, UT, USA, 84060
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.
Executives
Amit Munshi director, officer: President and CEO C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116
Robert Lisicki officer: EVP, Chief Commercial Officer C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Dallas Jayson Donald Alexander director AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Vincent Aurentz officer: Executive VP and CBO C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Tina Susan Nova director C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Christopher Cabell officer: EVP, Head of R&D, and CMO C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Manmeet Singh Soni director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Kieran Gallahue director PO BOX 684369, PARK CITY UT 84068
Katharine Knobil director C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVE., LEXINGTON MA 02421
Jennifer Jarrett director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Garry Arthur Neil director 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Oliver Fetzer director AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Laurie Stelzer officer: EVP & Chief Financial Officer 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Joan Schmidt officer: EVP, General Counsel & Sec C/O ARENA PHARMACEUTICALS, INC. 6154 NANCY RIDGE DRIVE SAN DIEGO CA 92121
Kevin Robert Lind officer: Executive VP and CFO C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121